IRWD icon

Ironwood Pharmaceuticals

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 16.7%
Negative

Positive
Zacks Investment Research
yesterday
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Positive
Zacks Investment Research
yesterday
Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
2 months ago
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Positive
The Motley Fool
2 months ago
Ironwood (IRWD) Q2 EPS Jumps 600%
Ironwood (IRWD) Q2 EPS Jumps 600%
Ironwood (IRWD) Q2 EPS Jumps 600%
Positive
Zacks Investment Research
2 months ago
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to break-even earnings per share a year ago.
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
Neutral
Business Wire
2 months ago
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance. “In the second quarter, LINZESS delivered $248 million in U.S. net sales with robust EUTRx demand growth of 10% year-over-year. Additionally, LINZESS net price was in-line with our expectations for the qu.
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
Negative
Zacks Investment Research
4 months ago
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
Negative
Zacks Investment Research
5 months ago
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Negative
Zacks Investment Research
5 months ago
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Neutral
Business Wire
5 months ago
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st.
Ironwood Pharmaceuticals Reports First Quarter 2025 Results